Manufacturer of Controlled Substances; Notice Of Application; Research Triangle Institute, 30327 [2012-12381]
Download as PDF
<![CDATA[
30327
Federal Register / Vol. 77, No. 99 / Tuesday, May 22, 2012 / Notices
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Application,
Alltech Associates, Inc.
[FR Doc. 2012–12326 Filed 5–21–12; 8:45 am]
BILLING CODE 4410–09–P
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 19, 2012,
Alltech Associates Inc., 2051 Waukegan
Road, Deerfield, Illinois 60015, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice Of Application;
Research Triangle Institute
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 12, 2012,
Research Triangle Institute, Hermann
Building, East Institute Drive, P.O. Box
12194, Research Triangle, North
Carolina 27709, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Schedule
Marihuana (7360) .........................
Cocaine (9041) .............................
I
II
srobinson on DSK4SPTVN1PROD with NOTICES
The Institute will manufacture
marihuana, and cocaine derivatives for
use by their customers in analytical kits,
reagents, and reference standards as
directed by the National Institute on
Drug Abuse.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 23, 2012.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12381 Filed 5–21–12; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
17:20 May 21, 2012
Jkt 226001
Drug
Drug
Schedule
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
4-Methylaminorex (cis isomer)
(1590).
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
4-Bromo-2,5-dimethoxy-amphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5-dimethoxy-amphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
N-Ethyl-1-phenylcyclohexylamine
(7455).
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470).
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Methamphetamine (1105) ............
1-phenylcyclohexylamine (7460) II
Phencyclidine (7471).
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
Phenylacetone (8501) ..................
1piperidinocyclohexanecarbonitrile (8603).
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) VII.
Ecgonine (9180) ...........................
Meperidine intermediate-B (9233)
Noroxymorphone (9668) VII.
Schedule
II
II
II
II
II
II
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 23, 2012.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12379 Filed 5–21–12; 8:45 am]
BILLING CODE 4410–09–P
I
I
DEPARTMENT OF LABOR
I
Approval of Information Collection
Requirements; Comment Request
I
Office of Federal Contract
Compliance Programs, Labor.
ACTION: Notice.
AGENCY:
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
The Department of Labor, as
part of its continuing effort to reduce
paperwork and respondent burden,
conducts a pre-clearance consultation
program to provide the general public
and Federal agencies with an
opportunity to comment on proposed
and continuing collections of
information in accordance with the
Paperwork Reduction Act of 1995
(PRA). 44 U.S.C. 3506(c)(2)(A). This
program helps to ensure that requested
data can be provided in the desired
format, reporting burden (time and
financial resources) is minimized,
collection instruments are clearly
understood, and the impact of collection
requirements on respondents can be
properly assessed. Currently, the Office
of Federal Contract Compliance
Programs is soliciting comments on its
SUMMARY:
E:\FR\FM\22MYN1.SGM
22MYN1
]]>Agencies
[Federal Register Volume 77, Number 99 (Tuesday, May 22, 2012)]
[Notices]
[Page 30327]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12381]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice Of Application;
Research Triangle Institute
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on April 12, 2012, Research
Triangle Institute, Hermann Building, East Institute Drive, P.O. Box
12194, Research Triangle, North Carolina 27709, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Cocaine (9041)............................. II
------------------------------------------------------------------------
The Institute will manufacture marihuana, and cocaine derivatives
for use by their customers in analytical kits, reagents, and reference
standards as directed by the National Institute on Drug Abuse.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 23, 2012.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-12381 Filed 5-21-12; 8:45 am]
BILLING CODE 4410-09-P
